How to Get Farxiga (Dapagliflozin) in Montana

What Farxiga Does and Why Montana Patients Seek It

Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that blocks glucose reabsorption in the proximal tubule of the kidney, lowering blood sugar while promoting mild osmotic diuresis. Its clinical value extends well beyond glycemic control. The FDA has approved Farxiga for three distinct indications: type 2 diabetes mellitus, heart failure (specifically in adults with New York Heart Association class II through IV symptoms), and chronic kidney disease at risk of progression 1.

The DAPA-HF trial (N=4,744) demonstrated that dapagliflozin 10 mg daily reduced the composite of cardiovascular death or worsening heart failure by 26% compared to placebo (hazard ratio 0.74 to 95% CI 0.65 to 0.85, P<0.001), with benefits observed regardless of baseline diabetes status 2. That finding changed practice guidelines across multiple specialties.

In Montana, where roughly 9.2% of adults carry a diabetes diagnosis according to CDC Behavioral Risk Factor Surveillance System data 3, access to SGLT2 inhibitors is a priority for primary care and cardiology practices statewide. Rural geography and limited specialist availability make telehealth a practical channel for initiating therapy. The remainder of this guide covers exactly how to obtain, fill, and afford a Farxiga prescription within the state.

Who Can Prescribe Farxiga in Montana

Any Montana-licensed prescriber with authority to write for prescription medications can prescribe dapagliflozin. This includes physicians (MD and DO), nurse practitioners (NP), and physician assistants (PA). Montana grants NPs full practice authority under Montana Code Annotated 37-8-102, meaning NPs can evaluate, diagnose, and prescribe independently without a collaborative physician agreement 4.

PAs in Montana prescribe under a supervision agreement with a physician, though the supervising physician does not need to be physically present. For a straightforward SGLT2 inhibitor prescription in a patient who meets labeled indications, any of these clinician types can manage the process from initial evaluation through ongoing monitoring.

Rural patients without nearby endocrinology or cardiology offices can work with their primary care provider. Dapagliflozin does not require specialist initiation per American Diabetes Association (ADA) Standards of Care 5. A family medicine NP in Miles City has the same prescriptive authority for Farxiga as an endocrinologist in Billings.

Using Telehealth to Get Farxiga in Montana

Montana permits telehealth prescribing for medications including SGLT2 inhibitors. The state enacted telehealth parity legislation (Montana SB 101, effective 2021) requiring private insurers to cover telehealth services at the same rate as in-person visits. The Montana Board of Medical Examiners recognizes audio-video consultations as a valid basis for establishing a provider-patient relationship and issuing prescriptions 6.

A telehealth visit for Farxiga follows a standard workflow. The clinician reviews your medical history, current medications, renal function labs, and cardiovascular risk profile. If dapagliflozin is appropriate, the prescription is sent electronically to your chosen pharmacy. The entire visit typically runs 15 to 25 minutes.

For Montana residents in underserved areas (and the state has 45 of 56 counties classified as primary care Health Professional Shortage Areas by HRSA), telehealth removes the barrier of a multi-hour drive to a prescribing clinician 7. Platforms operating in Montana must use clinicians licensed in the state, so confirm licensure before booking.

One practical consideration: your prescriber will want baseline labs before writing the prescription. Many telehealth platforms partner with national lab networks (Quest, Labcorp) that have draw sites in Billings, Missoula, Great Falls, Helena, Bozeman, and Kalispell. Patients in remote areas can use local hospital labs and forward results.

Required Labs Before Starting Farxiga

The Farxiga prescribing information specifies assessments that clinicians should complete before initiation. This is not optional paperwork. These labs protect against known risks.

Estimated glomerular filtration rate (eGFR): Dapagliflozin is indicated for CKD patients with eGFR as low as 25 mL/min/1.73 m², but the drug should not be started in patients on dialysis. The DAPA-CKD trial (N=4,304) enrolled patients with eGFR 25 to 75 and demonstrated a 39% reduction in the composite of sustained eGFR decline, end-stage kidney disease, or renal/cardiovascular death 8.

Hemoglobin A1c (if prescribed for type 2 diabetes): Establishes a baseline for tracking glycemic response. The ADA recommends an A1c target of <7% for most adults, though individualized goals apply 5.

Blood pressure: SGLT2 inhibitors lower systolic blood pressure by approximately 3 to 5 mmHg through natriuresis. Patients already on antihypertensives may need dose adjustments 9.

Volume status assessment: Dapagliflozin causes osmotic diuresis. Patients on loop diuretics or those with a history of hypotension warrant careful evaluation. The FDA label carries a warning for volume depletion, particularly in patients aged 65 and older 1.

Urinalysis or history of genital mycotic infections: SGLT2 inhibitors increase urinary glucose, which raises the risk of genital yeast infections. A meta-analysis in the BMJ (N=36,689 across 45 trials) found SGLT2 inhibitors roughly tripled the risk of genital mycotic infections compared to placebo, though events were predominantly mild 10.

Montana patients can get these drawn at any licensed lab. Results are typically available within 24 to 48 hours, so the total timeline from lab draw to prescription can be as short as two to three days.

Montana Medicaid Does Not Cover Farxiga: Your Alternatives

This is the single biggest access obstacle for low-income Montana residents. Montana Medicaid's preferred drug list does not include Farxiga. Patients relying solely on Medicaid will face a non-covered status, meaning the pharmacy claim will reject at the point of sale.

Several workarounds exist.

AstraZeneca Savings Card: Commercially insured patients (not Medicare, Medicaid, or other government programs) may qualify for the manufacturer copay card, which can reduce out-of-pocket cost to $0 per month. Eligibility is income-independent for those with qualifying commercial coverage. The card is available through the official Farxiga website and most prescribers can activate it during the visit.

AstraZeneca Patient Assistance Program (AZ&Me): Uninsured patients or those whose insurance does not cover the drug may qualify based on income (generally <400% of the federal poverty level, which in 2026 is approximately $62,400 for a single-person household). Approved patients receive the medication at no cost 11.

Prior authorization appeal through commercial insurance: If a patient has private insurance that initially denies coverage, the prescriber can submit a prior authorization. Documentation typically includes: diagnosis codes (E11.65 for type 2 diabetes with hyperglycemia, I50.x for heart failure, N18.x for CKD), lab results showing eGFR and A1c, documentation of failed first-line therapy (metformin intolerance or contraindication for diabetes indication), and a letter of medical necessity citing guideline recommendations.

The ADA 2024 Standards of Care recommend SGLT2 inhibitors as first-line add-on therapy for patients with established atherosclerotic cardiovascular disease, heart failure, or CKD, independent of A1c 5. Citing this guideline strengthens prior authorization requests considerably.

503A compounding pharmacies: Montana licenses 503A compounding pharmacies that can prepare dapagliflozin formulations. This path may offer lower cost for uninsured patients, though compounded versions are not AB-rated equivalents of the brand product. Patients should confirm that their prescriber is comfortable with a compounded formulation and that the pharmacy holds a valid Montana Board of Pharmacy license.

Montana Pharmacy Options and Fill Times

Farxiga is stocked at major chain pharmacies throughout Montana, including Walgreens, Albertsons, and independent community pharmacies. The drug is a standard oral tablet, not a specialty medication requiring cold chain or restricted distribution, so availability is broad.

Typical fill times after a prescription reaches the pharmacy:

• In-stock at local pharmacy: Same day or next business day.
• Needs to be ordered: 1 to 3 business days for chain pharmacies with regional distribution centers.
• Mail-order pharmacy: 3 to 7 business days. Some insurance plans mandate mail-order for 90-day supplies, which can reduce per-unit cost.
• 503A compounding pharmacy: 5 to 10 business days, depending on whether the pharmacy compounds dapagliflozin on-demand or maintains batch stock.

For patients in rural Montana communities without a nearby pharmacy, mail-order is often the most reliable option. Montana does not restrict mail-order prescription delivery for non-controlled substances. Dapagliflozin is not a controlled substance.

A 30-day supply of brand Farxiga 10 mg has an average cash price of approximately $550 to $620 without insurance or discount programs, based on national pricing data 12. Discount programs and the AstraZeneca savings card can lower this dramatically, and as of early 2026, generic dapagliflozin has entered the market following patent settlement, with generic cash prices ranging from $30 to $90 per month depending on the pharmacy.

Transferring an Existing Farxiga Prescription to Montana

Patients relocating to Montana from another state can transfer an active Farxiga prescription. The process is straightforward because dapagliflozin is not a controlled substance. Montana accepts prescription transfers from all U.S. states.

Steps: call your new Montana pharmacy and provide the name and phone number of your previous pharmacy. The receiving pharmacist contacts the transferring pharmacy to verify the prescription, remaining refills, and prescriber information. This takes 15 to 30 minutes in most cases. There is no requirement for a new office visit solely to transfer the prescription, though your new prescriber will eventually need to see you (in-person or via telehealth) to continue refills.

If your previous prescription was written by a clinician not licensed in Montana, the transferred fills already authorized will be honored, but future refills will require a Montana-licensed prescriber. Setting up care with a local or telehealth provider before your existing refills run out avoids any gap in therapy. Interrupting SGLT2 inhibitor therapy is not dangerous in the way stopping certain cardiac medications can be, but maintaining continuity preserves the cardiorenal benefits documented in DAPA-HF and DAPA-CKD 2 8.

Prior Authorization Documentation in Montana

When a Montana insurer requires prior authorization for Farxiga, the prescriber's office submits a request that typically includes the following:

1. Clinical diagnosis with ICD-10 codes. Common codes: E11.65 (type 2 diabetes with hyperglycemia), I50.22 (chronic systolic heart failure, NYHA class II), I50.32 (chronic diastolic heart failure), N18.3 or N18.4 (CKD stage 3 or 4).
2. Lab results. Most recent eGFR, A1c, and BNP or NT-proBNP (for heart failure indication).
3. Treatment history. Documentation of prior medications tried, particularly metformin for the diabetes indication. For heart failure, documentation that the patient is on guideline-directed medical therapy (beta-blocker, ACE inhibitor or ARB or ARNI, and mineralocorticoid receptor antagonist as tolerated).
4. Letter of medical necessity. A brief statement citing ADA, American Heart Association (AHA), or Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommending SGLT2 inhibitors for the patient's specific condition 13.

Turnaround time for prior authorization in Montana typically ranges from 24 to 72 hours for standard requests. Urgent requests (for inpatient-to-outpatient transitions, for example) can be processed in 24 hours or less. If denied, patients and prescribers can file an appeal. The AHA has published position statements noting that prior authorization barriers to guideline-recommended heart failure therapies, including SGLT2 inhibitors, delay care and worsen outcomes 14.

"For patients with heart failure, delays caused by prior authorization for SGLT2 inhibitors represent a measurable risk. The benefit of these agents is front-loaded; the separation of Kaplan-Meier curves in DAPA-HF was apparent within 28 days of randomization," noted the 2022 AHA policy statement on administrative barriers to heart failure therapy 14.

Safety Monitoring Once on Farxiga

After initiation, your prescriber will order follow-up labs. The standard monitoring schedule, per the 2024 KDIGO guidelines, includes renal function (eGFR and serum creatinine) at 1 month, then every 3 to 6 months 13. A reversible dip in eGFR of up to 10% to 15% is expected in the first weeks and is not a reason to discontinue. In DAPA-CKD, this initial eGFR dip was followed by a slower long-term decline compared to placebo, reflecting the drug's hemodynamic effect on intraglomerular pressure 8.

Watch for symptoms of diabetic ketoacidosis (DKA), which can occur at normal or near-normal glucose levels (euglycemic DKA). The FDA issued a Drug Safety Communication in 2015 identifying this risk across the SGLT2 inhibitor class 15. Signs include nausea, vomiting, abdominal pain, fatigue, and difficulty breathing. The incidence is low (approximately 0.1% to 0.2% in clinical trials), but patients should know to seek emergency care and to stop taking the medication if symptoms arise.

Genital mycotic infections, urinary tract infections, and volume depletion are the most common adverse effects. The DECLARE-TIMI 58 trial (N=17,160) reported genital infections in 0.9% of dapagliflozin patients versus 0.1% in the placebo group over a median follow-up of 4.2 years 16.

Montana patients using telehealth for ongoing monitoring should ensure their prescriber receives lab results directly from the lab's electronic health record system or patient portal. Keeping a consistent lab location simplifies result tracking across visits.

The ADA's 2024 Standards of Care state: "SGLT2 inhibitors with demonstrated cardiovascular benefit are recommended to reduce the risk of major adverse cardiovascular events and heart failure hospitalization, independent of baseline A1c or individualized A1c target" 5. For Montana patients who meet this profile, the clinical case for accessing Farxiga is supported by the highest level of guideline evidence.